Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The molecular basis for therapeutic concepts utilizing CD14

F Stelter1, M Bernheiden, R Menzel

  • 1Institute of Immunology and Transfusion Medicine, Ernst-Moritz-Arndt-University, Greifswald, Germany.

Progress in Clinical and Biological Research
|May 12, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma.

Scientific reports·2025
Same author

Biosorption of process-equipment-related leachables (PERLs) in biomanufacturing: A quantitative approach to study partitioning of PERLs in a cell culture system.

International journal of pharmaceutics·2023
Same author

First-year predictors of health-related quality of life changes in short-statured children treated with human growth hormone.

Journal of endocrinological investigation·2019
Same author

Comparative characterization of two galectins excreted-secreted from intestine-dwelling parasitic versus free-living females of the soil-transmitted nematode Strongyloides.

Molecular and biochemical parasitology·2018
Same author

A novel HLA variant, HLA-C*03:376, detected by next generation sequencing.

HLA·2018
Same author

A novel HLA-C variant, HLA-C*04:01:85, detected by next generation sequencing.

HLA·2018

Soluble CD14 (sCD14) shows therapeutic potential for septic shock. Alanine scanning identified key regions (9-13 and 91-101) crucial for lipopolysaccharide (LPS) binding and sCD14-mediated cell signaling.

Area of Science:

  • Immunology
  • Molecular Biology

Background:

  • CD14 is a myeloid cell receptor recognizing lipopolysaccharide (LPS) and Gram-negative bacteria.
  • Soluble CD14 (sCD14) offers potential therapeutic benefits for LPS-induced septic shock.

Purpose of the Study:

  • To investigate the functional domains of human CD14 involved in LPS binding and signaling.
  • To identify specific amino acid residues critical for CD14-LPS interaction and downstream cellular responses.

Main Methods:

  • Alanine scanning mutagenesis of human CD14 (amino acids 1-152).
  • Generation and characterization of 23 substitution mutants in CHO cells.
  • Assays for anti-CD14 antibody recognition, LPS/E. coli binding, and LPS-induced IL-6 release.

Main Results:

Related Experiment Videos

  • Twenty-one mutants expressed on cell surfaces, 18 secreted as soluble forms.
  • CD14(39-41,43-44)A mutant lost all LPS and E. coli binding ability.
  • A combined mutant CD14(9-13/57,59,61-63)A showed significantly reduced LPS interaction, suggesting a conformational LPS-binding site.
  • Regions 9-13 and 91-101 were identified as critical for sCD14-mediated LPS signaling.

Conclusions:

  • The LPS-binding site on human CD14 is a conformational epitope.
  • Specific N-terminal and internal regions of CD14 are essential for LPS recognition and downstream signaling pathways relevant to septic shock treatment.